Valuation: ALLOVIRPAR

Market Cap 49.21M 43.16M 39.98M 36.78M 69.57M 4.71B 70.93M 476M 187M 2.31B 185M 181M 7.99B P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -69.08M -60.59M -56.12M -51.63M -97.66M -6.61B -99.56M -669M -262M -3.25B -259M -254M -11.21B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day-4.05%
Current month-56.42%
Current year-56.42%
3 years 4.28
Extreme 4.275
87.17
5 years 4.28
Extreme 4.275
607.43
10 years 4.28
Extreme 4.275
1,126.08

Financials

2023 2024
Net sales - -
Net income -190M -167M -155M -142M -269M -18.23B -274M -1.84B -723M -8.95B -715M -699M -30.91B -58.77M -51.55M -47.74M -43.93M -83.09M -5.62B -84.7M -569M -223M -2.76B -221M -216M -9.54B
Net Debt -157M -137M -127M -117M -221M -14.98B -226M -1.52B -594M -7.36B -588M -575M -25.41B -118M -104M -96.09M -88.42M -167M -11.32B -170M -1.15B -449M -5.56B -444M -434M -19.2B
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change Volume
14/07/26 USD 4.275 -3.72% 23,772
10/07/26 USD 4.440 -1.11% 10,280
09/07/26 USD 4.490 -4.67% 16,084
08/07/26 USD 4.710 -2.48% 64,589
07/07/26 USD 4.830 +3.87% 22,464
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock